G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 115 filers reported holding G1 THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $90,000 | -39.6% | 11,849 | -19.1% | 0.00% | – |
Q4 2021 | $149,000 | -21.2% | 14,647 | +4.1% | 0.00% | -100.0% |
Q3 2021 | $189,000 | -51.4% | 14,070 | -20.6% | 0.00% | 0.0% |
Q2 2021 | $389,000 | +8.4% | 17,730 | +18.9% | 0.00% | 0.0% |
Q1 2021 | $359,000 | +48.3% | 14,910 | +11.1% | 0.00% | 0.0% |
Q4 2020 | $242,000 | +103.4% | 13,425 | +30.2% | 0.00% | 0.0% |
Q3 2020 | $119,000 | -54.1% | 10,309 | -3.4% | 0.00% | 0.0% |
Q2 2020 | $259,000 | -22.9% | 10,668 | -16.1% | 0.00% | -50.0% |
Q4 2019 | $336,000 | +5.3% | 12,714 | -9.3% | 0.00% | 0.0% |
Q3 2019 | $319,000 | -22.4% | 14,011 | +4.6% | 0.00% | 0.0% |
Q2 2019 | $411,000 | +62.5% | 13,391 | -12.1% | 0.00% | 0.0% |
Q1 2019 | $253,000 | -11.8% | 15,231 | +1.5% | 0.00% | 0.0% |
Q4 2018 | $287,000 | -66.1% | 15,003 | -7.2% | 0.00% | -66.7% |
Q3 2018 | $846,000 | +18.5% | 16,171 | -1.6% | 0.01% | +20.0% |
Q2 2018 | $714,000 | +29.6% | 16,431 | +10.4% | 0.01% | +25.0% |
Q1 2018 | $551,000 | +69.0% | 14,877 | -9.5% | 0.00% | +100.0% |
Q4 2017 | $326,000 | – | 16,438 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |